765 related articles for article (PubMed ID: 31704598)
61. Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
Cao M; Suo S; Zhang X; Wang X; Xu J; Yang W; Zhou Y
Biomed Res Int; 2021; 2021():1235314. PubMed ID: 33553421
[TBL] [Abstract][Full Text] [Related]
62. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
Bady P; Delorenzi M; Hegi ME
J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331
[TBL] [Abstract][Full Text] [Related]
63. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
64. Noninvasive prediction of IDH mutation status in gliomas using preoperative multiparametric MRI radiomics nomogram: A mutlicenter study.
Lu J; Xu W; Chen X; Wang T; Li H
Magn Reson Imaging; 2023 Dec; 104():72-79. PubMed ID: 37778708
[TBL] [Abstract][Full Text] [Related]
65. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
66. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H
J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005
[TBL] [Abstract][Full Text] [Related]
67. MRI features predict p53 status in lower-grade gliomas via a machine-learning approach.
Li Y; Qian Z; Xu K; Wang K; Fan X; Li S; Jiang T; Liu X; Wang Y
Neuroimage Clin; 2018; 17():306-311. PubMed ID: 29527478
[TBL] [Abstract][Full Text] [Related]
68. Molecular Characteristics of Thalamic Gliomas in Adults.
Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
[TBL] [Abstract][Full Text] [Related]
69. Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status.
He J; Ren J; Niu G; Liu A; Wu Q; Xie S; Ma X; Li B; Wang P; Shen J; Wu J; Gao Y
BMC Med Imaging; 2022 Aug; 22(1):137. PubMed ID: 35931979
[TBL] [Abstract][Full Text] [Related]
70. Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI.
Sha Y; Yan Q; Tan Y; Wang X; Zhang H; Yang G
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900232
[TBL] [Abstract][Full Text] [Related]
71. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
[TBL] [Abstract][Full Text] [Related]
72. High-order radiomics features based on T2 FLAIR MRI predict multiple glioma immunohistochemical features: A more precise and personalized gliomas management.
Li J; Liu S; Qin Y; Zhang Y; Wang N; Liu H
PLoS One; 2020; 15(1):e0227703. PubMed ID: 31968004
[TBL] [Abstract][Full Text] [Related]
73. Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features.
Shboul ZA; Chen J; M Iftekharuddin K
Sci Rep; 2020 Feb; 10(1):3711. PubMed ID: 32111869
[TBL] [Abstract][Full Text] [Related]
74. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
75. Residual Deep Convolutional Neural Network Predicts MGMT Methylation Status.
Korfiatis P; Kline TL; Lachance DH; Parney IF; Buckner JC; Erickson BJ
J Digit Imaging; 2017 Oct; 30(5):622-628. PubMed ID: 28785873
[TBL] [Abstract][Full Text] [Related]
76. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
[TBL] [Abstract][Full Text] [Related]
77. Prediction of malignant glioma grades using contrast-enhanced T1-weighted and T2-weighted magnetic resonance images based on a radiomic analysis.
Nakamoto T; Takahashi W; Haga A; Takahashi S; Kiryu S; Nawa K; Ohta T; Ozaki S; Nozawa Y; Tanaka S; Mukasa A; Nakagawa K
Sci Rep; 2019 Dec; 9(1):19411. PubMed ID: 31857632
[TBL] [Abstract][Full Text] [Related]
78. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
79. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
80. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.
Moon WJ; Choi JW; Roh HG; Lim SD; Koh YC
Neuroradiology; 2012 Jun; 54(6):555-63. PubMed ID: 21833736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
